
    
      There will be 3 dose cohorts of 15 subjects each. In Period 1, subjects will be randomized to
      either receive multiple doses of both tamsulosin HCl and solifenacin succinate as single
      entity tablets, or the combination tablet EC905. The alternate treatment will be provided in
      Period 2. The cohorts will be balanced for period effects and first-order carry over effects.
    
  